• Disc Medicine entered a first amendment to its 2024 loan agreement with Hercules Capital to extend availability for future advances.
• Drawdown of USD 30 million under the Tranche 1-B Advance.
• Split the existing USD 50 million Tranche 1-C Advance into USD 25 million available through March 31, 2027, USD 25 million Tranche 1-D through April 30, 2027.
• Extended draw periods for the Tranche 2 Advance to Dec. 15, 2027, Tranche 3 Advance to June 30, 2028.
• Revised minimum cash covenant to start testing on July 1, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-290542), on June 30, 2026, and is solely responsible for the information contained therein.